Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-038803
Filing Date
2025-03-13
Accepted
2025-03-13 16:30:24
Documents
96
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K cadl-20241231.htm   iXBRL 10-K 3188767
2 EX-4.2 cadl-ex4_2.htm EX-4.2 51692
3 EX-19.1 cadl-ex19_1.htm EX-19.1 117502
4 EX-23.1 cadl-ex23_1.htm EX-23.1 3119
5 EX-31.1 cadl-ex31_1.htm EX-31.1 15513
6 EX-31.2 cadl-ex31_2.htm EX-31.2 15537
7 EX-32.1 cadl-ex32_1.htm EX-32.1 16179
8 GRAPHIC img213924294_0.jpg GRAPHIC 267349
  Complete submission text file 0000950170-25-038803.txt   12420327

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cadl-20241231.xsd EX-101.SCH 1655231
98 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20241231_htm.xml XML 1738564
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-40629 | Film No.: 25736279
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)